The U.S. opioids market is estimated to be valued at USD 7.06 Bn in 2024 and is expected to exhibit a CAGR of 3.7% during the forecast period (2024-2031). Opioids are a class of drugs that include prescription pain relievers like oxycodone, hydrocodone, codeine, morphine, fentanyl, and others. They work by binding to opioid receptors in the brain and body to relieve pain. Since the late 1990s, pharmaceutical companies reassured the medical community that patients would not become addicted to opioid pain relievers, and healthcare providers began prescribing them at greater rates, which led to widespread overuse and increased addiction rates. This resulted in the current epidemic of opioid addiction and overdose deaths in the U.S.
Market Dynamics:
The U.S. opioids market is driven by the growing prevalence of chronic pain conditions in an aging population, as well as the risks of dependence and addiction associated with long term use. However, the market has also witnessed regulations and reforms to curb overprescribing and mitigate risks. Increased education of doctors and public about the judicious use of opioids present an opportunity to shift toward more balanced pain management approaches. Meanwhile, alternative therapies and non-opioid drugs are emerging as attractive alternatives to opioids for pain relief. Development of abuse-deterrent formulations also provides opportunities, though high development costs are a restraint.
Key Features of the Study:
- This report provides an in-depth analysis of the U.S. opioids market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the U.S. opioids market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes Pfizer, Inc., Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals PLC , Mundipharma International, Boehringer Ingelheim International GmbH., Collegium Pharmaceutical, Sun Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., Curaleaf, Purdue Pharma L.P., Cresco Labs, Trulieve, Teva Pharmaceutical Industries Ltd., Green Thumb Industries, Trevena, Inc., Par Pharmaceutical, and Emergent BioSolutions Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The U.S. opioids market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. opioids market.
Detailed Segmentation-
- By Drug Type:
- Oxycodone
- Hydrocodone
- Morphine
- Codeine
- Methadone
- Others (Meperidine, etc.)
- By Therapeutic Application:
- Pain Management
- Neuropathic Pain
- Back Pain
- Migraine
- Osteoarthritis Pain
- Cancer pain
- Others
- Cough Treatment
- Diarrhea Treatment
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles:
- Pfizer, Inc.
- Mallinckrodt Pharmaceuticals
- Hikma Pharmaceuticals PLC
- Mundipharma International
- Boehringer Ingelheim International GmbH.
- Collegium Pharmaceutical
- Sun Pharmaceutical Industries Ltd.
- Jazz Pharmaceuticals, Inc.
- Curaleaf
- Purdue Pharma L.P.
- Cresco Labs
- Trulieve
- Teva Pharmaceutical Industries Ltd.
- Green Thumb Industries
- Trevena, Inc.
- Par Pharmaceutical
- Emergent BioSolutions Inc.
